☆ 4.5 Review

A Comprehensive Review of the Pleiotropic Effects of Ticagrelor

CARDIOVASCULAR DRUGS AND THERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis

Rahul Gupta et al.

Summary: This study aimed to compare the safety and efficacy of different loading strategies of P2Y12 inhibitors in patients undergoing elective PCI. The results showed that although prasugrel and ticagrelor are known as more potent antiplatelet agents, their effects in preventing MI and stroke are marginal and do not translate into improved overall mortality and bleeding compared with clopidogrel.

CARDIOVASCULAR DRUGS AND THERAPY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevationmyocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

Anne H. Tavenier et al.

Summary: The study found that intravenous acetaminophen compared with intravenous fentanyl did not significantly affect platelet inhibition in patients with ST-elevation myocardial infarction (STEMI). However, acetaminophen resulted in significantly higher plasma levels of ticagrelor and provided effective pain relief.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials

Waiel Abusnina et al.

Summary: This meta-analysis aimed to investigate the efficacy and safety of potent oral P2Y12 inhibitors vs. clopidogrel in elderly patients with ACS. The results showed that compared to clopidogrel, the use of potent oral P2Y12 inhibitors was associated with a reduction in cardiovascular mortality, but no significant change in MACE outcomes, and an increased risk of bleeding events.

CARDIOVASCULAR REVASCULARIZATION MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials

Claudio Montalto et al.

Summary: This study aimed to examine the effect of available P2Y12 inhibitors on ischaemic and bleeding endpoints in older adults with ACS. The results showed that prasugrel was associated with a reduction in ischaemic events, while clopidogrel was associated with a reduction in bleeding events. Ticagrelor had the best effect on reducing stent thrombosis, but may not be the optimal choice for older adults.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

Jawad H. Butt et al.

Summary: This study investigated the 1-year risks of Staphylococcus aureus bacteraemia, sepsis, and pneumonia in patients undergoing percutaneous coronary intervention and treated with ticagrelor or clopidogrel. The results showed that treatment with ticagrelor was associated with significantly lower risks of Staphylococcus aureus bacteraemia, sepsis, and pneumonia compared to treatment with clopidogrel.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial

Masafumi Ono et al.

Summary: This study investigated the efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention (PCI) stratified according to their baseline white blood cell (WBC) count. The findings showed that ticagrelor monotherapy was more effective than aspirin monotherapy in reducing the primary endpoint in patients with lower WBC counts. However, there was no significant difference in the effectiveness of the two treatment strategies in patients with higher WBC counts, and there were no significant differences in bleeding risks between the two strategies regardless of the WBC groups.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Effect of ticagrelormonotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients

Sung-Jin Hong et al.

Summary: This study aimed to evaluate the effect of ticagrelor monotherapy after short-term dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on mortality. The results showed that ticagrelor monotherapy was associated with decreased all-cause mortality and bleeding risk without increasing the risk of cardiac death, ischemic stroke, acute myocardial infarction, and stent thrombosis.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Do We Really Need Aspirin Loading for STEMI?

Regina Ye et al.

Summary: Aspirin loading is recommended for patients with ST elevation myocardial infarction (STEMI) as soon as possible after presentation, but its effects on the therapeutic effects of other medications have not been studied. This review suggests that aspirin loading may attenuate the protective effects of statins, ticagrelor, morphine, and postconditioning in reducing myocardial infarct size. Further research is needed to investigate the effects of aspirin loading on these medications and to compare aspirin loading with alternative antiplatelet regimens in STEMI patients.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?

Hiroshi Asanuma et al.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis

Niklas Bergh et al.

Summary: This review compares the efficacy and safety of clopidogrel and ticagrelor as part of dual antiplatelet therapy in patients with acute coronary syndrome and older patients. The results show that there is little or no difference in all-cause mortality between the two drugs. Although not evident in older patients, it cannot be excluded that clopidogrel may be slightly less efficient in reducing the risk of cardiovascular mortality and myocardial infarction, whereas ticagrelor is probably more efficacious in reducing the risk of stent thrombosis. Clopidogrel results in a reduced risk of dyspnea and clinically significant bleeding, and in older people probably in a reduced risk of major bleeding.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ying Ma et al.

Summary: This study aimed to evaluate the impact of choosing ticagrelor or clopidogrel on bleeding risk and efficacy in East Asian patients with acute coronary syndrome. The results showed that compared to clopidogrel, ticagrelor had a higher risk of any bleeding, PLATO major bleeding, and dyspnea, but significantly reduced the risk of stent thrombosis.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis

Mengyi Sun et al.

Summary: This study compared the clinical outcomes of ticagrelor and clopidogrel in patients with ACS. The results showed that ticagrelor is not superior to clopidogrel in terms of MACE, but is associated with a higher risk of bleeding. Different PCI strategies, ethnicities, and countries may contribute to the different therapeutic effects of ticagrelor.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

Mehmet Koray Adali et al.

Summary: In this study, it was found that inflammatory parameters, including NLR, MHR, PLR, and SII, were significantly lower in ACS patients treated with ticagrelor compared to clopidogrel. This suggests that ticagrelor may have a positive impact on inflammatory response in PCI-treated ACS patients.

ACTA CARDIOLOGICA (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis

Qiufen Xie et al.

Summary: This study systematically reviewed the impact of CYP2C19 genotype on the pharmacodynamics and clinical outcomes of ticagrelor. The results indicated that Asian patients carrying any CYP2C19 loss-of-function allele might have a lower risk of bleeding events compared with non-carriers. However, the role of CYP2C19 genotype in the overall risk of pharmacodynamics and clinical endpoints was not significant.

BMC CARDIOVASCULAR DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack

Yongjun Wang et al.

Summary: This study investigated the short-term benefits and risks of ticagrelor with aspirin in patients with acute mild-moderate ischemic stroke or high-risk TIA. The results showed that ticagrelor significantly reduced major ischemic events from the first week and continued throughout the 30-day treatment period, while the risk of major hemorrhage increased in the first week and remained relatively stable thereafter.

NEUROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress

Ceylan Verda Bitirim et al.

Summary: Extracellular vesicles derived from ticagrelor-pretreated cardiomyocytes can attenuate hyperglycemia-induced oxidative stress and apoptosis, and improve endothelial cell migration and tube formation, providing a potential therapeutic approach for diabetic cardiomyopathy.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Antiplatelet therapy after percutaneous coronary intervention

Dominick J. Angiolillo et al.

Summary: Antiplatelet therapy is crucial for reducing thrombotic complications and ischemic events in patients undergoing percutaneous coronary interventions (PCI), but it is also associated with increased risk of bleeding. Advances in stent technologies and understanding of bleeding risks have led to the development of personalized antiplatelet treatment regimens. Recent research and guidelines have provided several options for antiplatelet therapy after PCI.

EUROINTERVENTION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Jean-Philippe Collet et al.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis

Lina Badimon et al.

Summary: Arachidonic acid is a common omega-6 polyunsaturated fatty acid that can produce various biologically active substances. It exists in esterified form in cell membrane phospholipids and is released through the actions of phospholipases, affecting important physiological processes such as blood coagulation and vascular functions.

CARDIOVASCULAR RESEARCH (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial

Byung Gyu Kim et al.

Summary: The study examined the age-dependent effects of ticagrelor monotherapy after 3-month DAPT compared to ticagrelor-based 12-month DAPT in patients with acute coronary syndrome. The results showed a greater reduction in major bleeding and cardiovascular events with ticagrelor monotherapy in patients aged 64 and older, indicating this strategy may be more beneficial for elderly patients with acute coronary syndrome.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

Xiangkai Zhao et al.

Summary: In elderly patients with ACS, aspirin plus ticagrelor reduces the risk of cardiovascular death and all-cause mortality but increases the risk of bleeding. Compared to clopidogrel, aspirin plus ticagrelor may prolong the lifetime of elderly ACS patients. The optimal dual antiplatelet therapy for elderly ACS patients may be a valuable direction for future research.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors

Ingrid Langer et al.

Summary: VIP and PACAP are neuropeptides that regulate intestinal processes through VPAC1, VPAC2, and PAC1 receptors. Due to lack of specificity, poor bioavailability, and short half-life, new therapeutic options are sought. Drug repositioning led to the identification of ticagrelor as a VPAC1 and VPAC2 inhibitor, showing an allosteric mechanism of action. Further studies on ticagrelor's binding modes and comparisons with cangrelor may improve selectivity for VIP and PACAP receptor sub-types.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention

Francesco Condello et al.

Summary: Among patients undergoing complex PCI, ticagrelor monotherapy after a short course of ticagrelor-based DAPT significantly reduced bleeding risk without increasing ischemic risk. More data are needed to definitively explain mortality benefits.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Mattia Galli et al.

LANCET (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/transient ischemic attack-Protocol for a systematic review and network meta-analysis

Gabriele Zitikyte et al.

Summary: This study will compare the efficacy of Ticagrelor and Aspirin versus Clopidogrel and Aspirin in preventing recurrent stroke and mortality in patients with minor ischemic stroke or transient ischemic attack up to 30 days.

PLOS ONE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor and the risk of infections during hospitalization in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Xing-Ji Lian et al.

Summary: The study compared the effects of ticagrelor and clopidogrel on infections among STEMI patients undergoing PCI, finding similar preventive effects on infections but slightly lower risks of in-hospital all-cause death and MACCE in the ticagrelor group.

ATHEROSCLEROSIS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction

Marie V. Hjortbak et al.

Summary: The study explored the translational cardioprotective potential of P2Y(12) inhibitors in acute myocardial ischemia/reperfusion injury, showing that ticagrelor may have better effects in reducing infarct size.

BASIC RESEARCH IN CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction

Muhammad Sabbah et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial

Remo H. M. Furtado et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome

Luca Baldetti et al.

AMERICAN JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Ticagrelor in Post-STEMI Adverse Ventricular Remodeling There Is More Than Meets the Platelet

Gemma Vilahur et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI)

Yongwhi Park et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2020)

添加到收藏夹

Article Hematology

Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial

Salahaddin Ubaid et al.

THROMBOSIS AND HAEMOSTASIS (2019)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria

Patrizio Lancellotti et al.

JAMA CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Reduces Ischemia-Reperfusion Injury Through the NF-κB-Dependent Pathway in Rats

Xiaogang Liu et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel

Hasseri Halim et al.

PLOS ONE (2019)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

S. Schuepke et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

P. Gabriel Steg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?

Joseph Allencherril et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

Borja Ibanez et al.

EUROPEAN HEART JOURNAL (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis

Giuseppe Tarantini et al.

AMERICAN HEART JOURNAL (2018)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Caffeine and incidence of dyspnea in patients treated with ticagrelor

Daniel Lindholm et al.

AMERICAN HEART JOURNAL (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function

Jonathon P. Audia et al.

BASIC RESEARCH IN CARDIOLOGY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs

Gemma Vilahur et al.

CARDIOVASCULAR RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

William R. Hiatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice

Yumei Ye et al.

CARDIOVASCULAR DRUGS AND THERAPY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine

Yochai Birnbaum et al.

CARDIOVASCULAR DRUGS AND THERAPY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Protective Effects of Ticagrelor on Myocardial Injury After Infarction

Gemma Vilahur et al.

CIRCULATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack

S. Claiborne Johnston et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Hematology

P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction

Johanne Silvain et al.

THROMBOSIS AND HAEMOSTASIS (2016)

添加到收藏夹

Article Chemistry, Medicinal

Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis

Michael R. Preusch et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Infarct Size Following Treatment With Second-Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study

Jamal N. Khan et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Understanding the Adverse Effects of Ticagrelor in Practice

Christopher B. Granger et al.

JAMA CARDIOLOGY (2016)

添加到收藏夹

Article Hematology

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

Yumei Ye et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings

Gilad D. Birnbaum et al.

CARDIOVASCULAR DRUGS AND THERAPY (2015)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Inflammation and Immunity in Diseases of the Arterial Tree Players and Layers

Peter Libby et al.

CIRCULATION RESEARCH (2015)

添加到收藏夹

Article Hematology

Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size An Adenosine and Cyclooxygenase-2-Dependent Effect

Manjyot K. Nanhwan et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Daniel Lindholm et al.

EUROPEAN HEART JOURNAL (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Adenosine-Mediated Effects of Ticagrelor Evidence and Potential Clinical Relevance

Marco Cattaneo et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome

Laurent Bonello et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Ezra A. Amsterdam et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

Gilles Montalescot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Cell Biology

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

Robert F. Storey et al.

PLATELETS (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Patrick T. O'Gara et al.

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Exploratory Study

Dimitrios Alexopoulos et al.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial

Owen Mogabgab et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2013)

添加到收藏夹

Review Cell Biology

Inflammation in atherosclerosis: a cause or a result of vascular disorders?

Ileana Manduteanu et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

P2Y12 platelet inhibition in clinical practice

Peter Damman et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Kenneth W. Mahaffey et al.

CIRCULATION (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

Philippe Gabriel Steg et al.

CIRCULATION (2010)

添加到收藏夹

Review Neurosciences

Caffeine and Adenosine

Joaquim A. Ribeiro et al.

JOURNAL OF ALZHEIMERS DISEASE (2010)

添加到收藏夹

Article Medicine, General & Internal

Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

Christopher P. Cannon et al.

LANCET (2010)

添加到收藏夹

Article Hematology

Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model

Kai Wang et al.

THROMBOSIS AND HAEMOSTASIS (2010)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist

Steen Husted et al.

CARDIOVASCULAR THERAPEUTICS (2009)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Lars Wallentin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat

Yumei Ye et al.

CARDIOVASCULAR DRUGS AND THERAPY (2008)

添加到收藏夹

Article Medicine, General & Internal

Prasugrel versus clopidogrel in patients with acute coronary syndromes

Stephen D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

Review Medicine, General & Internal

Mechanisms of disease: Myocardial reperfusion injury

Derek M. Yellon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin

Yochai Birnbaum et al.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2

S Atar et al.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Optimal windows of statin use for immediate infarct limitation -: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase

S Sanada et al.

CIRCULATION (2004)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Left ventricular remodeling after myocardial infarction - Pathophysiology and therapy

MGS Sutton et al.

CIRCULATION (2000)

添加到收藏夹

Article Surgery

Adenosine prevents activation of transcription factor NF-κB and enhances activator protein-1 binding activity in ischemic rat heart

CF Li et al.

SURGERY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.